Savara (NASDAQ:SVRA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Savara (NASDAQ:SVRA) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $6.00 price objective on the stock. HC Wainwright also issued estimates for Savara’s Q1 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.

SVRA has been the topic of a number of other reports. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company began coverage on shares of Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $8.83.

Savara Price Performance

Shares of NASDAQ SVRA opened at $2.91 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara has a fifty-two week low of $2.26 and a fifty-two week high of $5.34. The stock has a market cap of $499.41 million, a PE ratio of -6.77 and a beta of 0.60. The stock has a fifty day moving average of $2.72 and a 200-day moving average of $3.25.

Savara (NASDAQ:SVRA) last posted its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The business had revenue of $0.27 million during the quarter. Equities research analysts anticipate that Savara will post -0.45 earnings per share for the current year.

Hedge Funds Weigh In On Savara

Hedge funds and other institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. increased its holdings in Savara by 6.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 8,660,379 shares of the company’s stock valued at $26,587,000 after purchasing an additional 502,994 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Savara by 24.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company’s stock worth $482,000 after buying an additional 31,168 shares during the period. Woodline Partners LP grew its position in shares of Savara by 16.6% in the 4th quarter. Woodline Partners LP now owns 2,686,938 shares of the company’s stock worth $8,249,000 after buying an additional 381,743 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Savara by 33.2% during the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock valued at $33,079,000 after buying an additional 2,685,000 shares during the period. Finally, Squarepoint Ops LLC raised its holdings in shares of Savara by 178.1% during the fourth quarter. Squarepoint Ops LLC now owns 122,635 shares of the company’s stock valued at $376,000 after acquiring an additional 78,540 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.